Finoriq research workspace
ELI LILLY & Co (LLY) SEC Filings & Filing Highlights
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products. Review LLY SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; and strategic collaboration with Ascidian Therapeutics for discovery and development of therapies for undisclosed monogenic kidney diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Company
- ELI LILLY & Co (LLY)
- Ticker
- LLY
- Market Cap
- $1.1T
- Latest Price
- $1,150.5
- Industry
- Biotech & Pharma
ELI LILLY & Co (LLY) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ELI LILLY & Co (LLY).
| Event | Form | Date |
|---|---|---|
| ELI LILLY & Co: Corporate updateOn May 20, 2026, Eli Lilly and Company (the “Company”) completed its offering of $750,000,000 aggregate principal amount of its Floating Ra... | 8-K8.01 | 2026-05-20 |
| a) The four nominees for director were elected to serve three-year terms ending at the Company'...The Eli Lilly and Company (the “Company”) annual meeting of shareholders (the “2026 Annual Meeting”) was held on May 4, 2026. The total num... | 8-K5.07 | 2026-05-07 |
| ELI LILLY & Co: Earnings or resultsThe information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purpo... | 8-K2.02 | 2026-04-30 |
| ELI LILLY & Co: Earnings or resultsThe information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purpo... | 8-K2.02 | 2026-02-04 |
| On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Compa...On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a... | 8-K5.02 | 2025-11-21 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.